🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07479602
Recruiting Phase 4

Intranasal Dexmedetomidine-esketamine Administration and Postoperative Pain in Pediatric Patients

NCT07479602 · tracked via the Priya Life Science China tracker
Sponsor
Peking University First Hospital
Phase
Phase 4
Started
2026-04-07
Last updated
2026-04-09

Condition(s) studied

AdenotonsillectomyChildrenIntranasal AdministrationDexmedetomidineEsketaminePostoperative Pain

Investigational drug(s) / intervention(s)

Intranasal dexmedetomidine-esketamineIntranasal placebo (normal saline)

Intranasal dexmedetomidine-esketamine: A mixture of dexmedetomidine-esketamine combination will administered intranasally after anesthesia induction.

Intranasal placebo (normal saline): Placebo (normal saline) will administered intranasally after anesthesia induction.

Study summary

Postoperative pain after adenoid and tonsil surgery is significant, with approximately 75% of pediatric patients experiencing severe postoperative pain. Currently, there is a lack of clinical strategies to safely and effectively manage postoperative pain in children undergoing adenoid and tonsil surgery. Dexmedetomidine and esketamine can achieve appropriate sedation levels and alleviate postoperative pain when used in children. Both drugs can be administered intranasally, and their pharmacological effects complement each other, reducing side effects. This study aims to investigate whether intranasal administration of dexmedetomidine-esketamine combination can improve postoperative analgesia in children undergoing adenoid and tonsil surgery.

Eligibility

Sex
ALL
Min age
3 Years
Max age
7 Years
Healthy volunteers
No
Inclusion Criteria: * Aged 3-7 years old. * Scheduled to undergo adenoidectomy and/or tonsillectomy under general anesthesia. * Provides written informed consent by the guardian. Exclusion Criteria: * Unsuitable for intranasal administration due to nasal diseases (such as rhinitis, nasal polyps, or any condition causing nasal congestion). * Clearly diagnosed cardiovascular and respiratory diseases. * Communication barriers due to delayed neurological development or visual or hearing impairments. * Traumatic brain injury or neurosurgery. * Abnormal liver and kidney function (biomarkers higher than twice of the upper normal limits). * Amercian Society of Anesthesiologists classification ≥ III. * Body mass index higher than the 95th percentile of the age- and sex-standardized references. * Allergic to dexmedetomidine and/or esketamine. * Any other conditions that are deemed unsuitable for study participation.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Peking University First Hospital Beijing Beijing Municipality Recruiting

More Peking University First Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07479602 on ClinicalTrials.gov ↗ ← All trials in China